These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18270995)

  • 1. Sequence-based identification of specific drug target regions in the thymidylate synthase enzyme family.
    Ferrari S; Losasso V; Costi MP
    ChemMedChem; 2008 Mar; 3(3):392-401. PubMed ID: 18270995
    [No Abstract]   [Full Text] [Related]  

  • 2. Thymidylate synthase inhibitors.
    Ismail AS; Grem JL
    Cancer Chemother Biol Response Modif; 2001; 19():1-19. PubMed ID: 11686010
    [No Abstract]   [Full Text] [Related]  

  • 3. Design, synthesis and evaluation of potent thymidylate synthase X inhibitors.
    Esra Onen F; Boum Y; Jacquement C; Spanedda MV; Jaber N; Scherman D; Myllykallio H; Herscovici J
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3628-31. PubMed ID: 18513963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contributions of protein structure-based drug design to cancer chemotherapy.
    Jackson RC
    Semin Oncol; 1997 Apr; 24(2):164-72. PubMed ID: 9129687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the use of PIPSA to guide target-selective drug design.
    Henrich S; Richter S; Wade RC
    ChemMedChem; 2008 Mar; 3(3):413-7. PubMed ID: 18061917
    [No Abstract]   [Full Text] [Related]  

  • 6. Design and synthesis of multisubstrate analog inhibitors of one-carbon transfer reactions.
    Broom AD
    Fed Proc; 1986 Nov; 45(12):2779-83. PubMed ID: 3533643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Inhibition of thymidylate synthase in chemotherapy].
    Rode W
    Postepy Biochem; 1996; 42(2):133-40. PubMed ID: 8805186
    [No Abstract]   [Full Text] [Related]  

  • 8. Prized malaria drug target nailed.
    Rathod PK; Phillips MA
    Nat Struct Biol; 2003 May; 10(5):316-8. PubMed ID: 12714998
    [No Abstract]   [Full Text] [Related]  

  • 9. [Enzymes as starting points for pharmaceutical development].
    Wagner G
    Pharmazie; 1984 Mar; 39(3):190-4. PubMed ID: 6728894
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacological and toxicological evaluation of a new series of thymidylate synthase inhibitors as anticancer agents.
    Benassi L; Magnoni C; Giudice S; Bertazzoni G; Costi MP; Rinaldi M; Venturelli A; Coppi A; Rossi T
    Anticancer Res; 2006; 26(5A):3499-504. PubMed ID: 17094473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidylate synthase inhibitors.
    Takimoto CH; Diggikar S
    Cancer Chemother Biol Response Modif; 2005; 22():1-18. PubMed ID: 16110605
    [No Abstract]   [Full Text] [Related]  

  • 12. Thymidyl biosynthesis enzymes as antibiotic targets.
    Chernyshev A; Fleischmann T; Kohen A
    Appl Microbiol Biotechnol; 2007 Feb; 74(2):282-9. PubMed ID: 17216455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymidylate synthase inhibitors.
    Ackland SP; Clarke SJ; Beale P; Peters GJ
    Cancer Chemother Biol Response Modif; 2002; 20():1-36. PubMed ID: 12703198
    [No Abstract]   [Full Text] [Related]  

  • 14. Thymidylate synthase as a chemotherapeutic drug target: where are we after fifty years?
    Berger FG; Berger SH
    Cancer Biol Ther; 2006 Sep; 5(9):1238-41. PubMed ID: 17035726
    [No Abstract]   [Full Text] [Related]  

  • 15. [Advance in researches of drugs derived from marine bacteria].
    Lin BX; Huang ZQ; Xie LH
    Wei Sheng Wu Xue Bao; 2005 Aug; 45(4):657-60. PubMed ID: 16245893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitor specificity via protein dynamics: insights from the design of antibacterial agents targeted against thymidylate synthase.
    Ferrari S; Costi PM; Wade RC
    Chem Biol; 2003 Dec; 10(12):1183-93. PubMed ID: 14700626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacterial beta-ketoacyl-acyl carrier protein synthase III (FabH): an attractive target for the design of new broad-spectrum antimicrobial agents.
    Castillo YP; Pérez MA
    Mini Rev Med Chem; 2008 Jan; 8(1):36-45. PubMed ID: 18220983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hotspots in an obligate homodimeric anticancer target. Structural and functional effects of interfacial mutations in human thymidylate synthase.
    Salo-Ahen OM; Tochowicz A; Pozzi C; Cardinale D; Ferrari S; Boum Y; Mangani S; Stroud RM; Saxena P; Myllykallio H; Costi MP; Ponterini G; Wade RC
    J Med Chem; 2015 Apr; 58(8):3572-81. PubMed ID: 25798950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N4-hydroxy-5-halogeno-2'-deoxycytidine S and their 5'-mono-phosphates as inhibitors of thymidylate synthase and in vitro antileukemic agents.
    Felczak K; Bretner M; Dzik JM; Gołos B; Zieliński Z; Rode W; Kulikowski T
    Adv Exp Med Biol; 1998; 431():617-21. PubMed ID: 9598139
    [No Abstract]   [Full Text] [Related]  

  • 20. Alanine mutants of the interface residues of human thymidylate synthase decode key features of the binding mode of allosteric anticancer peptides.
    Tochowicz A; Santucci M; Saxena P; Guaitoli G; Trande M; Finer-Moore J; Stroud RM; Costi MP
    J Med Chem; 2015 Jan; 58(2):1012-8. PubMed ID: 25427005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.